Literature DB >> 21343953

Breast cancer bone metastases: denosumab or zoledronic acid?

Gabri van der Pluijm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21343953     DOI： 10.1038/nrendo.2011.18

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

Review 2.  Targeted therapy options for treatment of bone metastases; beyond bisphosphonates.

Authors:  J T Buijs; C C H J Kuijpers; G van der Pluijm
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 3.  Novel bone-targeted strategies in oncology.

Authors:  Sonia Vallet; Matthew R Smith; Noopur Raje
Journal:  Clin Cancer Res       Date:  2010-07-19       Impact factor: 12.531

4.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

Review 5.  Biochemical and molecular mechanisms of action of bisphosphonates.

Authors:  Michael J Rogers; Julie C Crockett; Fraser P Coxon; Jukka Mönkkönen
Journal:  Bone       Date:  2010-11-26       Impact factor: 4.398

Review 6.  Implications of bone metastases and the benefits of bone-targeted therapy.

Authors:  Allan Lipton
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

Review 7.  Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.

Authors:  Allan Lipton; Carsten Goessl
Journal:  Bone       Date:  2010-10-13       Impact factor: 4.398

8.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

Review 9.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 10.  Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.

Authors:  John M Chirgwin; Theresa A Guise
Journal:  J Cell Biochem       Date:  2007-12-15       Impact factor: 4.429
  10 in total
  2 in total

Review 1.  Anti-cancer actions of denosumab.

Authors:  Jameel Iqbal; Li Sun; Jeffrey I Mechanick; Mone Zaidi
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

2.  Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.

Authors:  Windy Dean-Colomb; Kenneth R Hess; Elliana Young; Terrie G Gornet; Beverly C Handy; Stacy L Moulder; Nuhad Ibrahim; Lajos Pusztai; Daniel Booser; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva
Journal:  Breast Cancer Res Treat       Date:  2012-12-15       Impact factor: 4.872
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.